In this article, we will discuss the 12 Most Promising Growth Stocks to Buy Now.

Technology stocks are flashing bearish signals as a rotation from all-time highs gathers pace. According to strategists at Bank of America, investors should start managing risk amid mounting headwinds, which could trigger a broader market selloff.

The sentiments come on the heels of tech-heavy Nasdaq 100 tumbling by more than 4% in the aftermath of solid employment data, fueling talks of interest rate hikes amid soaring inflation.

“The NDX rally extended slightly beyond expectation, breaking above 30,000. The trend became stretched relative to our measured move targets,” the strategist said, explaining that the 14-week Relative Strength Index (RSI) reached overbought levels and turned down, forming a bearish engulfing week.”

While chip stocks have led the rally in recent years, technicals signal the group is overbought, suggesting a period of higher volatility as valuations get out of hand. Bank of America strategists insist that technical analysis supports the need for investors to start playing defense as the risk-reward balance deteriorates.

Amid heightened volatility, promising growth stocks offer one of the best ways to shrug off the selloff. The stocks stand out for their stronger tailwinds in artificial intelligence, cloud security, e-commerce, and medical technology. Capital is expected to gravitate towards companies with an impressive record in combining growth with strong fundamentals, such as earnings growth and consistent cash flow generation.

With that in mind, let’s take a look at some of the most promising growth stocks to buy now.

Our Methodology

To compile a list of 12 Most Promising Growth Stocks to Buy Now, we used the Finviz screener to identify Growth stocks that boast 10% or more sales growth over the past five years and projected to grow earnings by over 20% over the next five years. We trimmed the list by focusing on stocks with a Buy or better rating from analysts and with an upside potential of more than 20%. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among elite hedge funds in Q1 2026. We ranked the stocks in ascending order based on the number of hedge funds that hold stakes in them.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Most Promising Growth Stocks to Buy Now

12. Argenx SE (NASDAQ:ARGX)

Stock Upside Potential: 20.98%

Expected 5-Year Earnings Growth: 32.29%

Number of Hedge Fund Holders: 42

Argenx SE (NASDAQ:ARGX) is one of the most promising growth stocks to buy now. On June 4, H.C. Wainwright reiterated a Buy rating and a $940 price target on Argenx SE (NASDAQ:ARGX). The positive stance is in response to the company’s recent data showing VYVGART’s effectiveness across autoimmune rheumatic diseases.

According to Luc Truyen, Chief Medical Officer at Argenx, the data underscore the rationale for targeting FcRn in autoimmune diseases and the potential to address unmet patient needs. The data support a favorable safety profile across multiple autoimmune rheumatic diseases. The company expects additional positive results from evaluating VYVGART in myositis and Sjogren’s disease next year.

Trial results from the ALKIVIA+ study indicate that VYVGART has the potential to deliver meaningful and sustained clinical benefit for patients with myositis. The candidate drug remains favorable across rheumatology indications. The US Food and Drug Administration has already approved a label expansion for VYVGART for the treatment of patients with generalized myasthenia gravis. The approval is based on data from the Phase 3 ADAPT SERON study.

Argenx SE (NASDAQ:ARGX) is a global immunology biotechnology company focused on developing antibody-based medicines for severe autoimmune diseases. Using proprietary research platforms like SIMPLE Antibody, they translate complex immunology breakthroughs into first-in-class therapies.

11. Snowflake Inc. (NYSE:SNOW)

Stock Upside Potential: 22.32%

Expected 5-Year Earnings Growth: 44.34%

Number of Hedge Fund Holders: 80

Snowflake Inc. (NYSE:SNOW) is one of the most promising growth stocks to buy now. On June 4, Cantor Fitzgerald reaffirmed its Overweight rating on Snowflake Inc. (NYSE:SNOW) with a $282 price target, highlighting upside from the current $241.28 share price and $83.6 billion market cap. The firm’s bullish stance aligns with broader Wall Street consensus, reflecting optimism around Snowflake’s evolving role in the data cloud space.

At the Snowflake Summit 26 in San Francisco, management outlined its transformation from a traditional data warehouse to an enterprise agentic control plane. This strategic shift is reinforced by the recent Natoma acquisition and a $6 billion AWS infrastructure commitment, signaling that capital allocation is firmly aligned with long‑term platform growth. Cantor noted rising conviction that Snowflake will benefit near‑term from embedding intelligence and AI into its contextual data layer.

Looking ahead, management projects GAAP profitability by Q4 fiscal 2028, supported by margin leverage and tighter control of stock‑based compensation. SBC is expected to decline from 40% of revenue in FY25 to 13% by FY28, addressing a key investor concern. Combined with an expanding total addressable market and AI tailwinds, Snowflake’s trajectory suggests meaningful upside potential for shareholders.

Snowflake Inc. (NYSE:SNOW) delivers cloud‑based data solutions through its Data Cloud platform, enabling businesses, partners, and providers to break down silos and unlock value. Its ecosystem supports diverse use cases, including data lakes, warehousing, engineering, application development, science, and secure data sharing.